

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00474)

SUPPLEMENTAL ANNOUNCEMENT
DISCLOSEABLE TRANSACTION
DISPOSAL OF 15% EQUITY INTEREST IN A SUBSIDIARY

Reference is made to the announcement of Aceso Life Science Group Limited (the “**Company**”) dated 11 May 2022 in respect of the Disposal (the “**Announcement**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

This announcement is made to provide the supplementary information on the identity of the ultimate beneficial owner of the Purchaser.

Based on the information available to the Company, the Purchaser is wholly-owned by Golden Leap Limited Partnership Fund (金鉞有限合夥基金) (“**Golden Leap**”), a limited partnership fund registered under the Limited Partnership Fund Ordinance (Cap. 637) on 11 June 2021. Hillier Investment Management Limited is the general partner who is ultimately responsible for the management and control of Golden Leap. Haitong International Asset Management Limited (海通國際資產管理有限公司) (“**HIAML**”) is the investment manager of Golden Leap. HIAML is incorporated in Hong Kong and holds a license to conduct Type 9 regulated activity (asset management). Golden Leap is investing in a diversified and comprehensive portfolio of investment products. As at the date of this announcement, it has invested in real estate and steel industries.

As stated in the Announcement, to the best of the knowledge, information and belief of the Directors, and having made all reasonable enquiries, the Purchaser and its ultimate beneficial owners are Independent Third Parties.

By order of the Board
Aceso Life Science Group Limited
Fok Chi Tak
Executive Director

Hong Kong, 17 May 2022

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Xu Haiying, Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; and three independent non-executive Directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.